RE: What are we worth….30 Jun 2022 10:49
The problem with this type of company is that it is very long term.
Prior to covid it was a 40p per share company. The reason it shot up was that it was seen as large revenues coming in very quickly when AVCT said they could get an LFT out very fast. But they didn't. It was a slam dunk, but still for whatever reason the promise did not materialise.
Now it has gone back to a typical, from a market perspective ,"Jam Tomorrow" bio-tech company but obviously we are 2 years further on and so far so good, so the SP has appreciated to where it is now.
The overhang I think for the market, as well as current market conditions which are poor, and the general concensus is to remain poor, is the potential for a cash raise before the company is sufficiently cash generative.
The £2m today is very helpful as has been AS's comments recently saying its not needed for some time yet but he has form for surprising the market in this regard.
So, in a difficult market like this with costs for all businesses rising dramatically, loss making companies get lumped together and it is eminently sensible for some risk to be taken off the table.
We might feel this is crazy for specifically AVCT (and hopefully we are right), but history shows the market is littered with companies not being able to sustain themselves through sharp downturns.
So maybe its not quite so illogical as it seems to many right now?